PATIENT PERCEPTION OF TREATMENT WITH LONG-TERM DUPILUMAB MONOTHERAPY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

被引：0
|
作者：
Simpson, E.
Lacour, J.
Beck, L.
Zhang, H.
Aamodt, K.
Rossi, A.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2021年 / 127卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P196
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [1] Patient wellbeing and perception of treatment effect with long-term dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis
    Simpson, E. L.
    Beissert, S.
    Beck, L. A.
    Zhang, H.
    Aamodt, K.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E139
  • [2] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Hamilton, Jennifer D.
    Graham, Neil M.
    Bieber, Thomas
    Rocklin, Ross
    Ming, Jeffrey E.
    Ren, Haobo
    Kao, Richard
    Simpson, Eric
    Ardeleanu, Marius
    Weinstein, Steven P.
    Pirozzi, Gianluca
    Guttman-Yassky, Emma
    Suarez-Farinas, Mayte
    Hager, Melissa D.
    Stahl, Neil
    Yancopoulos, George D.
    Radin, Allen R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
  • [3] Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis
    Cork, Michael J.
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Praestgaard, Amy
    Zhang, Haixin
    Wang, Zhixiao
    Rossi, Ana B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 79 - 79
  • [4] Dupilumab monotherapy provides long-term improvement in all Patient-Oriented Eczema Measure items in adults with moderate-to-severe atopic dermatitis
    Hussain, I.
    Bissonnette, R.
    Sanchez-Carazo, J. L.
    Ahn, K. J.
    Kataoka, Y.
    Praestgaard, A.
    Thomas, R. B.
    Bego-Le Bagousse, G.
    Wilson, G.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E157 - E158
  • [5] Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Simpson, Eric L.
    Thaci, Diamant
    de Bruin-Weller, Marjolein
    Deleuran, Mette
    Kataoka, Yoko
    Friedman, Adam J.
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Chen, Zhen
    Avetisova, Elena
    Zhang, Annie
    Nguyen, Tien, V
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 71 - 72
  • [6] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
  • [7] LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB UP TO 4 YEARS
    Blauvelt, A.
    Eichenfield, L.
    Sierka, D.
    Chen, Z.
    Khokhar, F.
    Marco, A. Rodriguez
    Shabbir, A.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S19 - S19
  • [8] Dupilumab provides long-term efficacy over 2.5 years in adults with moderate-to-severe atopic dermatitis
    Cork, Michael
    Beck, Lisa
    Bissonnette, Robert
    Wollenberg, Andreas
    Simpson, Eric
    Praestgaard, Amy
    Aamodt, Kimberly
    Rossi, Ana
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 69 - 69
  • [9] Long-term treatment with dupilumab minimizes use of systemic immunosuppressants as rescue medications in adults with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Blauvelt, A.
    Sher, L.
    Hussain, I.
    Rossi, A. B.
    Chen, Z.
    Shumel, B.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [10] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
12345